| **Supplementary Table S1. Investigator’s Choice (IC) Dosing Regimens** |
| --- |
| **Investigator’s Choice (route)** | **Dose, mg/m2** | **Dosing Days by Cycle** | **Cycle Duration, days** | **Maximum Doses/Cycles** |
| **Gemcitabine (IV)** | 1,250 | All cycles: D1, D8, and D15 | 28 | 6 cycles |
| 1,000 | All cycles: D1 and D15 | 28 | 6 cycles |
| **Rituximab (IV)a** | 375 | C1: D1, D8, D15, and D22; C4: D1; C6: D1; C8: D1; C10: D1b | 28 | 8 doses |
| **Etoposide (IV)** | 100 | All cycles: D1 to D5 | 28 | 6 cycles |
| 100 | All cycles: D1 to D3 | 28 | 6 cycles |
| **Etoposide (PO)** | 50 | All cycles: D1 to D21 | 28 | 6 cycles |
| 50 | All cycles: D1 to D14 | 28 | 6 cycles |
| 50 | All cycles: D1 to D10 | 28 | 6 cycles |
| **Oxaliplatin (IV)** | 100 | All cycles: D1 | 21 | 6 cycles |
| aRituximab was given to CD20+ patients only. bRituximab was given at 375 mg/m2 IV on days 1, 8, 15, and 22 of Cycle 1 and, if the patient achieved stable disease (SD) or better at week 12, then additional doses were given on day 1 of Cycles 4, 6, 8, and 10 for a total of 8 doses. For the prevention of cytokine release syndrome associated with the treatment of rituximab, a ≥125-mg dose of methylprednisolone or equivalent was allowed on C1D1.Abbreviations: C, cycle; D, day; IV, intravenously; PD, progressive disease; PO, orally; SD, stable disease. |